SABS vs REGN

For growth investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger pick with 1. 0% revenue growth year-over-year, versus -100. 0% for SAB Biotherapeutics, Inc. (SABS). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 4x trailing P/E (15. 6x forward), making it the more compelling value choice. Analysts rate SAB Biotherapeutics, Inc. (SABS) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Regeneron Pharmaceuticals, Inc.

(REGN) delivered a total return of +45. 4%, compared to -96. 2% for SAB Biotherapeutics, Inc. (SABS). Over 10 years, the gap is even starker: REGN returned +96. 0% versus SABS's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), SAB Biotherapeutics, Inc.

(SABS) is the lower-risk stock at 0. 80β versus Regeneron Pharmaceuticals, Inc. 's 0. 81β — meaning REGN is approximately 1% more volatile than SABS relative to the S&P 500. On balance sheet safety, SAB Biotherapeutics, Inc. (SABS) carries a lower debt/equity ratio of 4% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Regeneron Pharmaceuticals, Inc.

(REGN) is pulling ahead at 1. 0% versus -100. 0% for SAB Biotherapeutics, Inc. (SABS). On earnings-per-share growth, the picture is similar: SAB Biotherapeutics, Inc. grew EPS 78. 5% year-over-year, compared to 8. 2% for Regeneron Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus 0. 0% for SAB Biotherapeutics, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus 0. 0% for SABS. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SABS: 84.

2% to $7. 00.

In this comparison, REGN (0.

5% yield) pays a dividend. SABS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 81)). Both have compounded well over 10 years (REGN: +96. 0%, SABS: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SABS is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.